Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH)
O. Sitbon, R. N. Channick, M. Delcroix, H. A. Ghofrani, P. Jansa, F. O. Le Brun, S. Mehta, L. Perchenet, T. Pulido, L. J. Rubin, B. K. S. Sastry, G. Simonneau, R. Souza, A. Torbicki, N. Galiè (Le Kremlin-Bicêtre, France; Boston, San Diego, United States Of America; Leuven, Belgium; Giessen, Germany; Prague, Czech Republic; Allschwil, Switzerland; London, Canada; Mexico City, Mexico; Hyderabad, India; São Paulo, Brazil; Otwock, Poland; Bologna, Italy)
Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Session: Pulmonary hypertension: improving treatment in PAH
Session type: Oral Presentation
Number: 3419
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Sitbon, R. N. Channick, M. Delcroix, H. A. Ghofrani, P. Jansa, F. O. Le Brun, S. Mehta, L. Perchenet, T. Pulido, L. J. Rubin, B. K. S. Sastry, G. Simonneau, R. Souza, A. Torbicki, N. Galiè (Le Kremlin-Bicêtre, France; Boston, San Diego, United States Of America; Leuven, Belgium; Giessen, Germany; Prague, Czech Republic; Allschwil, Switzerland; London, Canada; Mexico City, Mexico; Hyderabad, India; São Paulo, Brazil; Otwock, Poland; Bologna, Italy). Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH). Eur Respir J 2014; 44: Suppl. 58, 3419
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: